Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...
Morning Overview on MSN
The FDA approved baxdrostat, a new pill that lowers blood pressure when other drugs fail
Adults whose blood pressure stays dangerously high despite taking three or more medications now have a new option. The FDA ...
In a small cohort of patients with Cushing’s disease, most had their urinary free cortisol normalized after being ...
Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.
Vertex Pharmaceuticals Incorporated announced Monday it will acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or ...
Biopharmaceutical firm Lundbeck has announced preliminary Phase II Part A data from its ongoing study evaluating asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal ...
A once-daily pill that blocks a key adrenal receptor slashed androgen levels by 67% while allowing most patients to reduce their steroid doses to normal physiologic levels, Crinetics Pharmaceuticals ...
Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.
OVERLAND PARK, Kan. , May 19, 2026 /PRNewswire/ -- Dechra is proud to announce the U.S. Food and Drug Administration's (FDA) approval of CosACTHen® (cosyntropin injection), the first and only ...
The National Drug Control Strategy is prepared biennially by the Office of National Drug Control Policy. This document provides a strategic roadmap for the Administration to continue dismantling the ...
Two-year CAHtalyst data show crinecerfont sustains androgen reduction and lowers glucocorticoid doses in children with congenital adrenal hyperplasia. Two-year data from the phase 3 CAHtalyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results